Preoperative neutrophil‐to‐lymphocyte ratio predicts the prognosis of esophageal squamous cell cancer patients undergoing minimally invasive esophagectomy after neoadjuvant chemotherapy. Issue 7 (30th August 2021)

• Record Type: Journal Article
• Authors: Kato, Takashi; Oshikiri, Taro; Goto, Hironobu; Urakawa, Naoki; Hasegawa, Hiroshi; Kanaji, Shingo; Yamashita, Kimihiro; Matsuda, Takeru; Nakamura, Tetsu; Suzuki, Satoshi; Kakeji, Yoshihiro
• Is Part Of: Journal of surgical oncology. Volume 124:Issue 7(2021)
• Page Start: 1022
• Page End: 1030
• Publication Date: 2021-08-30
• Subjects: esophageal squamous cell cancer -- minimally invasive esophagectomy -- neoadjuvant chemotherapy -- neutrophil‐to‐lymphocyte ratio; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26611
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Background: One of the primary treatment for resectable advanced esophageal squamous cell cancer (ESCC) is neoadjuvant chemotherapy (NAC) followed by minimally invasive esophagectomy (MIE). Because the neutrophil‐to‐lymphocyte ratio (NLR) is a widely reported prognostic factor in several cancers, we investigated whether the preoperative NLR is a biomarker in ESCC patients treated with NAC and MIE. Methods: In this study, we investigated 174 ESCC patients who underwent MIE from January 2010 to December 2015, including 121 patients who received NAC. The cutoff value of the NLR was analyzed using the receiver operating characteristic curve. Multivariate analyses were performed to clarify independent prognostic factors for overall survival (OS). Results: The cutoff value of the NLR for OS in 121 patients who received NAC was 2.5 ng/ml, and the area under the curve was 0.63026 ( p = 0.0127). The 5‐year OS rate was 64% in those with an NLR <2.5 and 39% in those with an NLR ≥2.5. According to multivariate analysis, NLR ≥2.5, pathological T, pathological N, and intraoperative blood loss of >415 ml were independent poor prognostic factors. Conclusions: NLR is a biomarker of prognosis in ESCC patients who undergo MIE after NAC.